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The hGLP-1R is a target for the treatment of type 2 diabetes and belongs to the class B family of GPCRs. Like
other class B GPCRs, the GLP-1R contains an N-terminal signal peptide (SP) and undergoes N-linked
glycosylation, which are important for its trafficking andmaturation. This study analysed the role of the SP,
the hydrophobic region after the SP (HRASP), glycosylation and the conserved residues within the
N-terminus in GLP-1R trafficking. HGLP-1R targeted to the cell surface showed no SP, and the SP deleted
mutant, but not the mutants defective in SP cleavage, showed cell surface expression, demonstrating the
importance of SP cleavage for hGLP-1R cell surface expression. The N-terminal deletions of hGLP-1R
revealed that theHRASP, not the SP, is essential for cell surface expression of GLP-1R. Further, inhibition of
hGLP-1R glycosylation prevented cell surface expression of the receptor. Mutation of Trp39, Tyr69 and Tyr88,
which are required for agonist binding, in the GLP-1R abolished cell surface expression of the receptor
independent of the SP cleavage or N-linked glycosylation. In conclusion, the N-terminus of hGLP-1R
regulates receptor trafficking and maturation. Therefore this study provides insight into the role of
hGLP-1R N-terminus on the receptor cell surface expression.
G
lucagon like peptide-1 (GLP-1) is a polypeptide hormone secreted by the intestinal L-cells into the blood
in response to food intake1–3. It is an effective insulinotropic agent, which lowers blood glucose levels and
increases insulin secretion1,4,5. It acts as an agonist to the GLP-1 receptor (GLP-1R), a family B G-protein
coupled receptor (GPCR). The binding of GLP-1 to the GLP-1R results in insulin secretion from pancreatic
b-cells, making human GLP-1R (hGLP-1R) an important target in the treatment of type 2 diabetes1,6.
The family B GPCRs contain a N-terminal domain signal peptide (SP) sequence that is often critical for the
synthesis and processing of the receptor7. The SP is about 20 amino acids (aa) long and contains a run of
hydrophobic residues. The first stage of protein targeting, during its synthesis, is insertion into the endoplasmic
reticulum (ER) by binding to the signal recognition particle (SRP), which is usually mediated by the SP8. For
example, deleting the SP sequence of the thyrotropin receptor (TR) abolished its functionality9,10. However, the SP
of the corticotropin-releasing factor (CRF) type 2a receptor, although present, is incapable of mediating ER
targeting11,12. Further, the SP of the CRF1 receptor is required for its expression but not for its function13. TheGLP-
1R contains a cleavable N-terminal SP (23 aa long), its cleavage was not required for synthesis of the receptor but
was essential for cell surface expression of the receptor14. Mutation of the SP (Ala21Arg) to prevent its cleavage has
been shown to result in retention of the GLP-1R within the ER. Further, a mutation of Glu34 was shown to
facilitate GLP-1R cell surface expression when the SP was deleted14. The aa sequence following the SP in the GLP-
1R, Gly27-Trp39, is relatively hydrophobic and it has previously been suggested that this region may be recognised
by the SRP for synthesis of the receptor14,15.
GPCRs synthesised in the ER translocate to the Golgi before being targeted to the cell surface. In this process,
GPCRs undergo post- or co-translational modifications including glycosylation, methylation, phosphorylation,
sulfation and lipid addition16,17. The N-linked glycosylated GPCRs are processed further in the ER and Golgi
before translocation and insertion into the plasma membrane18. The GLP-1R has been shown to undergo N-
linked glycosylation at positions Asn63, Asn82 and Asn115 within the ER19,20.
The hGLP-1R has three residues, Trp39, Tyr69 and Tyr88, within its N-terminal domain that are important for
agonist binding21–23. Trp39 has importance in maintaining the structure of the N-terminal domain of the GLP-1R
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by interacting with Tyr42, Phe66 and the adjacent disulphide bond
(Cys46-Cys71)24. It has been demonstrated that GLP-1 could not bind
and activate the GLP-1R when Trp39 was substituted with Ala or
Phe21. Further, Phe22, Ile23 and Leu26 of GLP-1 interacts with Trp39
in addition to Val36, Asp67, Tyr69, Arg121 and Leu123 of the GLP-1R22.
Tyr69, which is centrally locatedwithin theN-terminal domain, inter-
acts with Asp67 and has been shown to be involved in GLP-1 binding
to its receptor23. Tyr88 is involved in making the hydrophobic agonist
binding site, which interacts with Leu32 of GLP-1 and Leu26 of
Exendin-422,23. Although, Trp39, Tyr69 and Tyr88 residues within the
GLP-1R have been shown to be required for agonist binding, their
role in hGLP-1R trafficking, function andN-linked glycosylation are
currently unknown.
TheGLP-1R is amajor therapeutic target in the treatment of type 2
diabetes, therefore a better understanding of its membrane traffick-
ing is of high importance. This study determined that the SP is
cleaved in the mature hGLP-1R. Cell surface expression was almost
abolished with a mutation of the SP (A21R) to prevent its cleavage,
demonstrating that the cleavage of the SP was essential for cell sur-
face expression of the hGLP-1R. Although the role of the SP in family
B GPCR trafficking is well established, the significance of the hydro-
phobic region after the SP (HRASP) is unclear. Here, the HRASPwas
shown to be necessary for efficient hGLP-1R trafficking to the cell
surface. Further, this study indicated that the hGLP-1R undergoesN-
linked glycosylation and only the mature fully glycosylated form is
found at the cell surface. It was also demonstrated that preventing
cleavage of the SP inhibited hGLP-1R cell surface expression by
affecting N-linked glycosylation. Additionally, mutating Trp39,
Tyr69 and Tyr88 within the hGLP-1R abolished cell surface expression
of the receptor without affectingN-linked glycosylation and cleavage
of the SP.
Results
HGLP-1R expressing at the cell surface shows no SP. It has been
shown previously that the mature hGLP-1R expressing at the cell
surface is without the SP (1–23 aa)14. To confirm whether the SP is
cleaved off from the mature hGLP-1R that is targeted to the plasma
membrane, constructs containing a GFP-epitope at the C-terminus
and VSVG-epitope at the N-terminus before (SP-VSVG) or after the
SP (VSVG-SP) were generated (Figure 1A).HEK293 cells transfected
with these constructs were analysed for hGLP-1R cell surface
expression by ELISA (Figure 1D), immunofluorescence (Figure 1F)
and flow cytometry (Figure 1G) using the anti-hGLP-1R and anti-
VSVG antibodies. HEK293 cells expressing the SP-VSVG construct
showed cell surface expression of the receptor with both antibodies.
However, HEK293 cells expressing the VSVG-SP construct showed
signal at the cell surface with the anti-hGLP-1R antibody but not with
the VSVG antibody (100 6 0.58% versus 0 6 0.58% by ELISA and
93.8 6 2.61% versus 1.83 6 1.07% by flow cytometry with the anti-
hGLP-1R antibody [p, 0.001] versus the anti-VSVG antibody [p.
0.05], respectively). This result suggested that the SP is cleaved in the
membrane targeted hGLP-1R.
Both the SP-VSVG and VSVG-SP constructs showed a doublet
(,65 kDa and ,85 kDa in size) when the lysates of HEK293 cells
transfected with these constructs were immunoblotted with the anti-
GFP antibody (Figure 1C). In addition, the SP-VSVG but not the
VSVG-SP construct showed a doublet in the immunoblot probed
with the anti-VSVG antibody, indicating that the SP is cleaved off
from the hGLP-1R before it is targeted to the cell surface. Further,
whenHEK293 cells expressing these constructs were subjected to cell
surface biotinylation, only a single band at,85 kDa was observed in
the total lysate (Figure 1B). This demonstrated the ,85 kDa band
represents the mature form of the hGLP-1R that targeted to the cell
surface.
The GLP-1R is a Gas coupled GPCR and therefore the activity of
the receptor was assessed bymeasuring cAMP produced in hGLP-1R
expressing cells stimulated with agonist (Figure 1E). The VSVG-SP
construct had 99.57 6 0.43% (p . 0.05) cAMP accumulation com-
pared to the SP-VSVG construct, confirming the VSVG-SP is func-
tionally no different from the SP-VSVG construct. Furthermore, the
cAMP producing activity of SP-VSVG (which contains both VSVG
and GFP tags) is similar to that of the hGLP-1R with no tag or either
of the VSVG-tag or GFP-tag, indicating that the attachment of the
VSVG and GFP tags to the hGLP-1R had no effect on the activity of
the receptor (Figure S1). For further experimentation, the SP-VSVG
construct was used as the wild type (WT) control.
Cleavage of the SP is necessary for targeting the hGLP-1R to the
cell surface.Next, the importance of the SP cleavage in hGLP-1R cell
surface expression was determined. The cell surface expression of the
hGLP-1R without the SP (DSP), the hGLP-1R containing the SP
replaced with viral SP (VSP-DSP) and the hGLP-1R defective in
cleaving the SP (A21R) was compared to the SP-VSVG WT
control (Figure 2A). HEK293 cells transfected with these
constructs were analysed for their effect on hGLP-1R cell surface
expression (assessed by ELISA [Figure 2C], immunofluorescence
[Figure 2E] and flow cytometry [Figure 2F] using the anti-hGLP-
1R antibody) and activity (assessed by cAMP [Figure 2D]). The DSP
construct showed cell surface expression (assessed by ELISA [97.43
6 2.57%, p. 0.05], immunofluorescence and flow cytometry [1006
0.58%, p . 0.05]) similar to that of the SP-VSVG WT control.
Additionally, the DSP construct showed 95.24 6 2.55% (p . 0.05)
agonist induced cAMP production, confirming the hGLP-1R
without the SP is functionally similar to the control hGLP-1R. In
contrast, VSP-DSP and A21R constructs showed very little cell
surface expression (2.33 6 0.64% and 7.82 6 2.73% by ELISA, and
1.9 6 1.7% and 4.40 6 2.21% by flow cytometry, p , 0.001,
respectively), which was confirmed by immunofluorescence. The
cAMP activity of the VSP-DSP and A21R constructs in agonist
stimulated cells was also low (16.18 6 1.25% and 24.09 6 1.47%,
p, 0.001, respectively). Immunoblotting of the cell lysates expressing
the above mentioned constructs suggested that the SP of VSP-DSP and
A21R was not cleaved and as a result produced a single band at the
lower molecular weight of ,65 kDa with both the anti-GFP and
anti-VSVG antibodies (Figure 2B), confirming the expression of an
immature receptor. This result demonstrated that the SP is specific
to the hGLP-1R and mutating this sequence prevents cleavage of the
SP and thereby targeting of the hGLP-1R to the cell surface.
The sequence after the SP is required for hGLP-1R cell surface
expression. A number of deletions were made within the HRASP of
the hGLP-1R and analysed for their effect on the cell surface
expression and activity of the receptor (Figure 3A). For this
purpose, the cell surface expression of the N-terminal deleted
hGLP-1R mutants in HEK293 cells was analysed by ELISA
(Figure 3C). Removal of either 24 aa (DN24) or 30 aa (DN30)
from the N-terminal domain had no effect on hGLP-1R cell
surface expression (98.15 6 2.12% and 94.39 6 2.65%, p . 0.05,
respectively). However, deleting 35 aa (DN35) from the N-terminus
significantly reduced hGLP-1R cell surface expression and deleting
40 aa (DN40) abolished the cell surface expression altogether (17.86
0.61% and 0.21 6 0.16, p , 0.001, respectively). These results were
also confirmed by immunofluorescence (Figure 3E). Additionally,
the cAMP production of the receptor in agonist stimulated cells
reflected cell surface expression of the receptor (Figure 3D).
Agonist induced cAMP production of the DN24 and DN30
mutants (96.73 6 3.28% and 98.21 6 0.89%, p . 0.05,
respectively) were similar to that produced by the WT. In contrast,
hGLP-1R activity was significantly reduced when either 35 aa
(DN35) or 40 aa (DN40) were deleted from the N-terminal
domain (28.82 6 6.32% and 17.53 6 2.99%, p , 0.001,
respectively). Consequently, the region between 31–40 aa was
deleted (D31–40) from the hGLP-1R and analysed for the deletions
www.nature.com/scientificreports
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effect on hGLP-1R cell surface expression and cAMP production.
Cell surface expression (1.2 6 1.32%, p , 0.001) and cAMP
production (16.36 6 0.17%, p , 0.001) of the hGLP-1R were
almost abolished in the D31–40 mutant when compared to that of
the WT, indicating the importance of this region in trafficking the
receptor to the cell surface. Immunofluorescence confirmed these
results and showed hGLP-1R expression to be intracellular.
Immunoblotting confirmed that the reduced cell surface
expression of these deletion mutants was not due to alterations in
their expression levels (Figure 3B).
N-linked glycosylation is essential for hGLP-1R cell surface
expression. The hGLP-1R has been shown to be N-linked
glycosylated at positions Asn63, Asn82 and Asn115 within the
ER19,20. Therefore, HEK293 cells transfected with either the WT
SP-VSVG, DN145 or N63, 82, 115L constructs (Figure 4A) were
used to assess the importance of N-linked glycosylation in hGLP-
1R cell surface expression. Immunoblotting of the SP-VSVG WT
control showed the doublet at ,65 kDa and ,85 kDa (Figure 4B).
Treatment of SP-VSVG with a N-linked glycosylation inhibitor,
tunicamycin, shifted this doublet to ,60 kDa and 65 kDa. This
shift is used as a readout assay to assess hGLP-1R N-linked
glycosylation and showed that the hGLP-1R is N-linked
glycosylated. The hGLP-1R with the N-terminal domain
removed (DN145) showed only a single band at ,50 kDa in
immunoblotting. As the glycosylation sites were removed in the
Figure 1 | HGLP-1R expressing at the cell surface shows no SP. (A) HEK293 cells transfected with SP-VSVG andVSVG-SP constructs. (B) Total and cell
surface biotinylated hGLP-1R expression was assessed by immunoblotting using the anti-GFP antibody. (C) Total hGLP-1R expression was assessed by
immunoblotting using the anti-VSVG and anti-GFP antibodies. (D) Cell surface expression was assessed by ELISA using the anti-VSVG and anti-hGLP-
1R antibodies. (E) Agonist stimulated cAMP production was measured to assess hGLP-1R activity. (F) Immunofluorescence showing cell surface
expression of hGLP-1R, EGFP (green) and the anti-hGLP-1R antibody (red) overlay shown in yellow and nuclear staining with DAPI in blue. (G) Cells
surface expression of hGLP-1R constructs assessed by flow cytometry. Data are mean 6 SEM, n 5 3, n.s. p . 0.05; *** p , 0.001.
www.nature.com/scientificreports
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DN145 mutant, no change in mobility was seen when treated with
tunicamycin. Additionally, the N63, 82, 115L mutant, with all
three N-linked glycosylation sites mutated, of the hGLP-1R
showed a single band at ,60 kDa, which was also unaltered by
treatment with tunicamycin.
HGLP-1R glycosylation can be removed by treatment with both
PNGase F and Endo H, indicating the receptor is N-linked glycosy-
lated25. PNGase F cleaves oligomannoses and both hybrid and com-
plex N-glycans whereas Endo H cleaves oligomannoses and some
hybrid glycans. Therefore, the WT SP-VSVG, DN145 or N63, 82,
115L constructs were digested with Endo H or PNGase F enzymes
and analysed for their band pattern by immunoblotting (Figure 4C).
Treatment of the SP-VSVGWT control lysate with Endo H caused a
shift in the lower band mobility only from ,65 kDa to ,60 kDa.
However, treatment with PNGase F shifted both bands to,60 kDa
and 65 kDa, which mimicked the effect of tunicamycin and thereby
confirmed that the hGLP-1R is N-linked glycosylated by oligoman-
noses and both hybrid and complexN-glycans in themature form. In
contrast, the lysates of HEK293 cells expressing either the DN145 or
N63, 82, 115Lmutants showed no shift in band pattern when treated
with either Endo H or PNGase F, confirming that they are not
glycosylated.
The deleted (DN145) andmutated (N63, 82, 115L) hGLP-1R con-
structs were used to assess the importance of N-linked glycosylation
for cell surface expression of the receptor by ELISA (Figure 4E) and
immunofluorescence (Figure 4G). HGLP-1R cell surface expression
was abolished in both mutations when compared to theWT (0.48 6
0.48% and 0.14 6 0.07%, p, 0.001, respectively). Further, when cell
expressing the SP-VSVG control construct was treated with tunica-
mycin, cell surface expression was abolished (1.94 6 0.64%,
p , 0.001). This was confirmed further by immunofluorescence
where cell surface expression was seen for the SP-VSVG construct
with good colocalisation between GFP-tag and cell surface staining
with the anti-hGLP-1R antibody. However, the DN145 and
N63, 82, 115L mutants and the SP-VSVG construct treated
with tunicamycin only showed intracellular expression of GFP
and no cell surface expression with the anti-hGLP-1R antibody.
Immunoblotting demonstrated that the reduction in cell surface
expression of the mutants was not a result of reduced protein
expression (Figure 4D). Consistent with the reduced cell surface
expression, the DN145 and N63, 82, 115L mutants and the SP-
VSVG construct treated with tunicamycin caused reduced cAMP
production in agonist stimulated cells (14.25 6 0.29%, 13.61 6
0.93% and 11.08 6 1.61%, p , 0.001, respectively, Figure 4F).
Figure 2 | Cleavage of the SP is required for hGLP-1R cell surface expression. (A) HEK293 cells transfected with the indicated hGLP-1R constructs.
(B) Total hGLP-1R expressionwas assessed by immunoblotting using the anti-VSVG and anti-GFP antibodies. (C)Cell surface expressionwas assessed by
ELISA using the anti-hGLP-1R antibody. (D) Agonist stimulated cAMP production was measured to assess hGLP-1R activity. (E) Immunofluorescence
showing cell surface expression of hGLP-1R, EGFP (green) and the anti-hGLP-1R antibody (red) overlay shown in yellow and nuclear staining with DAPI
in blue. (F) Cells surface expression of hGLP-1R constructs was analysed by flow cytometry. Data are mean 6 SEM, n 5 3, n.s. p. 0.05; *** p, 0.001.
www.nature.com/scientificreports
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Therefore, preventing hGLP-1R glycosylation by either deleting the
N-terminal domain or mutating the glycosylation sites within the N-
terminal domain drastically reduced cell surface expression of the
receptor.
Effect of point mutations within the N-terminal domain on the
cell surface expression of the hGLP-1R. A number of N-terminal
residues conserved across the family B GPCRs were mutated within
the hGLP-1R to assess their effect on cell surface expression of the
receptor (estimated by ELISA [Figure 5B] and immunofluorescence
[Figure 5D]) and activity (assessed by cAMP accumulation
[Figure 5C]). The total protein expression of the mutants was
determined by immunoblotting using both the anti-GFP and anti-
VSVG antibodies (Figure 5A). Substitution of the negatively charged
Glu34 with a positively charged Lys residue (E34K) had no significant
effect on cell surface expression (101.6 6 1.59%, p. 0.05) or activity
(98.45 6 0.26%, p . 0.05) of the receptor. Total protein expression
levels of the E34K mutant were similar to that of the SP-VSVG
control construct. The W39A mutation significantly reduced
hGLP-1R cell surface expression (25.12 6 2.43%, p , 0.001) and
agonist stimulated cAMP production (21.72 6 2.4%, p , 0.001).
Additionally, the Y69A mutant of the hGLP-1R showed very low
cell surface expression (3.74 6 0.8%, p , 0.001) and reduced
agonist induced cAMP production (18.91 6 2.3%, p , 0.001).
Further, the Y88A mutation within the N-terminal domain of the
hGLP-1R almost abolished cell surface expression of the receptor
(2.30 6 1.05%, p , 0.001) and showed an even further reduction
in cAMP production (16.44 6 3.65%, p , 0.001). Immunoblot
analysis confirmed that the reduction in cell surface expression of
these mutants was not due to alterations in the mutants protein
expression. Consistent with the reduction in the cell surface
expression and cAMP producing activity, only a single band was
seen at ,65 kDa for these three mutations, indicating the
immature receptor. Immunofluorescence also supported the ELISA
results as intracellular expression was seen with GFP but no cell
surface staining was observed with the anti-hGLP-1R antibody.
Effect of SP, HRASP and conserved residue mutants on hGLP-1R
N-linked glycosylation. The importance of the SP, the HRASP and
conserved residues (Glu34, Trp39, Tyr69 and Tyr88) within the hGLP-
1R N-terminus on its N-linked glycosylation was determined. For
this purpose, cells expressing the constructs were treated without or
with tunicamycin and the cell lysates analysed by immunoblotting
using the anti-GFP antibody. Like the SP-VSVG WT control
construct, the SP deleted construct (DSP) showed a doublet in
immunoblotting and the doublet mobility was altered with
tunicamycin treatment. This suggested the DSP mutant was N-
linked glycosylated in the same way as the WT. The hGLP-1R
mutants that prevented cleavage of the SP (VSP-DSP and A21R)
only showed a single band at ,65 kDa and the band mobility was
unaltered when treated with tunicamycin, indicating that these
mutants were not N-linked glycosylated (Figure 6A). This is most
likely because the SP prevents access to the N-linked glycosylation
sites, as it is not cleaved in these mutants. Additionally, the mutants
with deletions within the HRASP of the N-terminus (DN35, DN40
and D31–40) showed a single band at ,65 kDa and a shift in the
doublet mobility was seen when treated with tunicamycin, which
suggests that these mutants are still glycosylated (Figure 6B).
When the W39A, Y69A and Y88A mutants were left untreated
with tunicamycin, a single band at,65 kDa was observed indicating
the immature form of the receptor. However, when treated with
tunicamycin there was a shift in the doublet mobility to ,60 kDa
and 65 kDa demonstrating these mutations still allowed the receptor
to be N-linked glycosylated (Figure 6C). Additionally, the E34K
Figure 3 | The sequence after the SP is essential for hGLP-1R cell surface expression. (A) HEK293 cells were transfected with the indicated N-terminal
deleted constructs. (B) Total hGLP-1R expression was assessed by immunoblotting using the anti-VSVG and anti-GFP antibodies. (C) Cell surface
expression was assessed by ELISA using the anti-hGLP-1R antibody. (D) Agonist stimulated cAMP production wasmeasured to assess hGLP-1R activity.
(E) Immunofluorescence showing cell surface expression of hGLP-1R, EGFP (green) and the anti-hGLP-1R antibody (red) overlay shown in yellow and
nuclear staining with DAPI in blue. Data are mean 6 SEM, n 5 3, n.s p . 0.05; *** p , 0.001.
www.nature.com/scientificreports
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mutant showed a doublet similar to that of theWT control in immu-
noblotting and the doublet mobility also altered with tunicamycin
treatment. These results suggest that N-linked glycosylation of the
receptor is unaltered with the E34K mutation.
The W39A, Y69A and Y88A mutations do not affect cleavage of
the SP. The W39A, Y69A and Y88A mutants in the SP-VSVG,
VSVG-SP and DSP constructs were used to determine whether
these mutations affect cleavage of the SP. The lysates of HEK293
cells expressing these mutants were subjected to immunoblotting
with both the anti-GFP and anti-VSVG antibodies to assess total
hGLP-1R expression and their effect on its SP cleavage
(Figure 7A). The W39A, Y69A and Y88A mutations did not
prevent cleavage of the SP when expressed in the SP-VSVG
construct. This and expression of these mutants in the DSP
construct showed expression with both the anti-GFP and anti-
VSVG antibodies. However, expression of the VSVG-SP construct
with these mutations only showed signal with the anti-GFP antibody
but not with the VSVG antibody, suggesting the SP is still cleaved. If
the mutations had affected cleavage of the SP, then the mutation
would have abolished expression of the VSVG-SP construct and
allowed expression of the DSP construct at the cell surface. This is
because there would be no SP to be cleaved in the DSP construct. In
immunofluorescence, hGLP-1R cell surface expressionwas seenwith
good colocalisation of GFP and the anti-hGLP-1R antibody in all
constructs (SP-VSVG, VSVG-SP and DSP) without the mutations.
However, only intracellular expressionwas seenwithGFP and no cell
surface staining with the anti-hGLP-1R antibody for all constructs
with the N-terminal mutations (Figure 7B). Taken together, this data
suggests that the W39A, Y69A and Y88A mutations did not affect
hGLP-1R cell surface expression by preventing cleavage of the SP.
Discussion
The hGLP-1R construct containing the VSVG-epitope tag at the N-
terminal domain before the SP sequence (VSVG-SP) showed signal
with the anti-hGLP-1R antibody but not with the anti-VSVG anti-
body, which indicated that the mature receptor expressed at the cell
surface is without its SP. Further, stimulation of cells expressing the
VSVG-SP with GLP-1 agonist stimulated cAMP production, con-
firming that the receptor without the SP is functionally active. These
results are in agreement with a previous study, which showed the
Figure 4 | N-linked glycosylation is essential for hGLP-1R cell surface expression. (A) HEK293 cells were transfected with either SP-VSVG, DN145 or
N63, 82, 115L plasmid DNA. (B) Cells were treated without or with 5 mg/ml tunicamycin for 48 h. The cells were lysed and the cell lysates were
immunoblotted with the anti-GFP antibody. (C) Post nuclear supernatant fractions of HEK293 cells were treated with either no enzyme, Endo H or
PNGase F for 60 min at 37uC and immunoblotted with the anti-GFP antibody. (D) Total hGLP-1R expression was assessed by immunoblotting using the
anti-GFP antibody. (E) Cell surface expression was assessed by ELISA using the anti-hGLP-1R antibody. (F) Agonist stimulated cAMP production was
measured to assess hGLP-1R activity. (G) Immunofluorescence showing cell surface expression of hGLP-1R, EGFP (green) and the anti-hGLP-1R
antibody (red) overlay shown in yellow and nuclear staining with DAPI in blue. Data are mean 6 SEM, n 5 3, *** p , 0.001.
www.nature.com/scientificreports
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mature hGLP-1R expressed at the cell surface is without the SP14.
These findings are also consistent with that of other family B GPCRs
including the vasoactive intestinal peptide (VPAC1) receptor26 and
CRF1 receptor13 where the SP is cleaved during synthesis. However,
the SP of VPAC1 was found to play a critical role in the receptors
targeting as deletion of the SP resulted in the synthesis but prevented
trafficking of the receptor to the cell surface. It was suggested that the
SP of the VPAC1 receptor is cleaved during trafficking to the plasma
membrane, most likely in the ER26. Additionally, the SP is of the
CRF1 receptor reduced cell surface expression but still retained its
functionality13. The hGLP-1R with the SP deletion (DSP), was shown
in this study to function exactly like the receptor with the SP present.
This contradicts a previous study, which showed the SP deleted
hGLP-1R is synthesised but does not express at the cell surface14.
The reason for the variation in results is unclear. In this study, the
hGLP-1RDSP was expressed with the VSVG-epitope tag at the N-
terminus whereas Huang et al (2010) expressed the same deletion
construct with a HA-epitope tag. However, it was observed that the
hGLP-1RDSP without any epitope tag at the N-terminus also targets
to the cell surface, indicating that the difference in the N-terminal tag
between studies may not be the reason for variation in the results.
Within this study, the hGLP-1R showed specificity to its SP sequence
because replacing it with the viral SP (VSP-DSP) allowed protein
synthesis but the cell surface expression was reduced. The A21R
mutation (-3 position of the SP cleavage site) allowed synthesis of
the hGLP-1R but prevented cleavage of the SP and therefore cell
surface expression was reduced, which is consistent with a previous
study14. Taken together, this study demonstrates that cleavage of the
SP is required for hGLP-1R cell surface expression and the SP
sequence is specific to the hGLP-1R. This is similar to the specificity
demonstrated for the CRF1, as replacement of the CRF1 SP with the
CRF2a SP abolished expression of the receptor11.
The aa sequence following the SP, Gly27-Trp39, is relatively hydro-
phobic (HRASP) and it has previously been suggested that this
region may be recognised by the SRP and allow for subsequent syn-
thesis of the receptor14,15. A similar region within the endothelin B
receptor (ETBR), Gln28-Trp34, was shown to be important in receptor
trafficking to cell surface by facilitating translocation across the ER
membrane27. To examine the role of the HRASP in hGLP-1R traf-
ficking, deletions were made within the HRASP region and assessed
for their effect on hGLP-1R cell surface expression. Deleting up to
30 aa of the N-terminal domain of the hGLP-1R had no effect on cell
surface expression of the receptor, whereas deletion of up to 40 aa or
31–40 aa abolished hGLP-1R cell surface expression. Therefore,
these results suggest that residues 31–40 within the HRASP are
important for hGLP-1R cell surface expression and cAMP produc-
tion. However, the 31–40 aa deletion within the hGLP-1R had no
effect on the cleavage of the SP or N-linked glycosylation, indicating
Figure 5 | The effect of various point mutations within the N-terminal domain of hGLP-1R on the cell surface expression of the receptor.HEK293 cells
were transfected with the indicatedN-terminal mutated constructs. (A) Total hGLP-1R expression was assessed by immunoblotting using the anti-VSVG
and anti-GFP antibodies. (B) Cell surface expression was assessed by ELISA using the anti-hGLP-1R antibody. (C) Agonist stimulated cAMP
production was measured to assess hGLP-1R activity. (D) Immunofluorescence showing cell surface expression of hGLP-1R, EGFP (green) and the anti-
hGLP-1R antibody (red) overlay shown in yellow and nuclear staining with DAPI in blue. Data are mean 6 SEM, n 5 3, n.s p . 0.05; *** p , 0.001.
Figure 6 | The effect of the SP, HRASP and conserved residue mutations
on hGLP-1R glycosylation. HEK293 cells transfected with SP (A),
HRASP (B) or the conserved residue (C) mutant constructs treated
without or with 5 mg/ml tunicamycin for 48 h. The cells were lysed and the
cell lysates were immunoblotted with the anti-GFP antibody.
www.nature.com/scientificreports
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that the HRASP is not required for either cleavage of the SP or N-
linked glycosylation of the receptor. It is possible that, like in the
ETBR, this region may be important in hGLP-1R translocation
across the ERmembrane, but requires further studies to confirm this
possibility.
The GLP-1R expressed in CCL39 fibroblasts28, HEK29314 and
CHO cells20 has previously been shown to produce a two band pat-
tern in immunoblotting, representing different N-linked glycosyla-
tion states. Consistent with this, the hGLP-1R expressed in HEK293
cells in this study showed a doublet in immunoblotting. Further,
treatment with tunicamycin, an N-linked glycosylation inhibitor29,
or deletion of the N-terminus (DN145) ormutating the glycosylation
sites (N63, 82, 115 L) prevented glycosylation of the hGLP-1R, con-
firming the hGLP-1R is glycosylated in the N-terminus. Moreover,
hGLP-1R glycosylation can be removed by treatment with both
PNGase F and Endo H, indicating the receptor is N-linked glycosy-
lated. The lysates of cell surface biotinylated hGLP-1R expressing
cells showed only the top band of the characteristic two band pattern
in immunoblotting, demonstrating it as the fully glycosylated and
mature receptor present at the cell surface. This is consistent with a
previous study, which showed that only the high molecular weight
band of the rat GLP-1R binds the GLP-1 agonist28. Taken together,
the data in this study confirmed that only the fully glycosylated and
mature receptor is found at the cell surface and that mutations and
deletions of the glycosylation sites prevented cell surface expression
and activity of the receptor. Additionally, tunicamycin inhibited gly-
cosylation of the SP deleted (DSP) mutant confirming it also under-
went N-linked glycosylation. This study demonstrated that
preventing cleavage of the SP (A21R or VSP) also inhibits N-linked
glycosylation, suggesting the SP may prevent access to the glycosyla-
tion sites required for hGLP-1R cell surface expression.
In addition to conserved glycosylation sites, the hGLP-1R contains
a number of amino acids within the N-terminal domain that are
highly conserved among family B GPCRs. A substitution of Glu34
to a positively charged residue has previously been shown to partially
compensate for the lack of the SP, where no GLP-1R expression was
demonstrated14. However, in this study the E34K mutation within
the hGLP-1R showed no significant effect on the cell surface express-
ion of the receptor. This is expected since the SP deleted (DSP)
mutant showed no effect on hGLP-1R cell surface expression. It
has previously been shown that a mutation of Trp39 abolished
GLP-1 binding to the GLP-1R, as the imidazole ring structure in this
position is important for agonist binding21,23. In this study, theW39A
mutation abolished hGLP-1R cell surface expression, demonstrating
that the imidazole ring structure at this position is also required for
cell surface expression of the receptor. Tyr69 and Tyr88 within the
Figure 7 | W39A, Y69A and Y88A mutations do not affect cleavage of the SP within the hGLP-1R. (A) Total hGLP-1R expression in HEK293 cells of
W39A, Y69A and Y88A mutants in SP-VSVG, VSVG-SP or DSP constructs was assessed by immunoblotting using the anti-VSVG and anti-GFP
antibodies. (B) Immunofluorescence showing cell surface expression of hGLP-1R, EGFP (green) and the anti-hGLP-1R antibody (red) overlay shown in
yellow and nuclear staining with DAPI in blue.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 7410 | DOI: 10.1038/srep07410 8
hGLP-1R have also been shown to be important in binding to the
agonist, Exenatide, but the reason for this was undetermined22,23. In
this study, the Tyr69 and Tyr88 mutations caused a significant loss in
hGLP-1R cell surface expression. The Trp39, Tyr69 and Tyr88 mutants
interfered with neither cleavage of the SP nor N-linked glycosylation
of the receptor and therefore it is unlikely that these mutations had
any effect on the stability of the receptor. The exact reason for these
mutations affecting hGLP-1R maturation and thereby its cell surface
expression is still unclear. However, it is possible that thesemutations
may affect trafficking of the N-linked glycosylated hGLP-1R to the
Golgi or interfere with further processing within the ER and Golgi.
This is an area requiring further investigation.
In summary, this study revealed that the SP sequence of the hGLP-
1R is cleaved during processing of the receptor. Cleavage of the SP is
not essential for hGLP-1R synthesis but is required for glycosylation
and trafficking of the receptor to the cell surface. Moreover, the SP is
specific to the hGLP-1R. The hGLP-1R is N-linked glycosylated and
only a fully glycosylated receptor is present at the cell surface.
Furthermore, the sequence within the HRASP, 31–40, was found
to be critical for hGLP-1R cell surface expression but not for cleavage
of the SP or glycosylation of the receptor. The conserved residues,
Trp39, Tyr69 and Tyr88, within the N-terminal domain were required
for cell surface expression of the hGLP-1R asmutating these residues
abolished cell surface expression while not interfering with cleavage
of the SP or glycosylation of the receptor. Overall, the results pre-
sented in this study suggest that the SP may prevent access to Asn63,
Asn82 and Asn115 glycosylation sites within hGLP-1R. With cleavage
of the SP, the glycosylation sites are exposed and the receptor under-
goes N-linked glycosylation. The glycosylated receptor then traffics
to the Golgi and then to the plasma membrane. The HRASP (31–
40 aa) and Trp39, Tyr69 and Tyr88 residues are critical for hGLP-1R
cell surface expressing and most likely play a role in trafficking the
receptor from the ER or interfere with further processing within the
ER and Golgi (Figure 8).
Methods
Antibodies and other reagents. The primary antibodies used were rabbit anti-
vesicular stomatitis virus glycoprotein (VSVG) (Immunoblotting, Abcam
Biochemicals), mouse anti-VSVG (ELISA and immunofluorescence, Sigma), mouse
anti-green fluorescent protein (GFP) (Roche), mouse anti-hGLP-1R (ELISA and
immunofluorescence, R&D Systems), mouse anti-hGLP-1R (Immunoblotting, Santa
Cruz). The Cy3-conjugated anti-mouse immunoglobulin G (IgG) secondary
antibody (Jackson Laboratories) was used for immunofluorescence. The horseradish
peroxidase (HRP)-conjugated anti-mouse and anti-rabbit IgG (GE Healthcare)
secondary antibodies were used for immunoblotting. Enhanced chemiluminescence
(ECL) select reagent was obtained fromGEHealthcare. GLP-1 (Liraglutide) was from
Novo Nordisk. All other chemicals were from Sigma unless otherwise stated.
Plasmids. The full-length hGLP-1RDN23 cDNA was amplified from mammalian
gene collection (MGC) clone 142053 (Source Bioscience) by polymerase chain
reaction (PCR) using High Fidelity Taq DNA polymerase (Roche Applied Science)
and sequence specific primers containing EcoRI restriction site andVSVG-tag coding
sequence (59 primer), and SalI restriction site and no stop codon (39 primer)30. SP-
VSVG-hGLP-1RDN23 cDNA was amplified by overlap PCR using VSVG-hGLP-
1RDN23 cDNA as the template, the sense primer, containing EcoRI restriction site,
the SP (1–23 aa) coding sequence followed by VSVG coding sequence and 39 primer.
The cDNA was digested with EcoRI and SalI, and cloned in frame into the same sites
of pEGFP-N1 vector (Clontech) for expression as the N-terminus VSVG-tagged
(after the SP) and the C-terminus GFP-tagged fusion protein inmammalian cells (SP-
VSVG-hGLP-1RDN23-GFP). The point mutations within the hGLP-1R were
generated usingQuickchange II XL site-directedmutagenesis kit (Stratagene) and SP-
VSVG-hGLP-1RDN23-GFP plasmid as the template31. The mutants with internal
deletions (D) within the N-terminus of hGLP-1R were generated using Q5 site
directed mutagenesis kit (New England Biolabs) and SP-VSVG-hGLP-1RDN23-GFP
plasmid as the template.
Cell culture and transfection. Human embryonic kidney 293 (HEK293) cells were
maintained at 37uC in a 5% CO2 humidified environment in Dulbecco’s modified
Eagle medium (DMEM; serum free medium [SFM]) supplemented with 10% foetal
calf serum, 2 mM glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin (full
serum medium [FSM]). Cells were transiently transfected for 48 h using JetPrime
transfection reagent (Polyplus; 2 ml/mg DNA) according to the manufacturer’s
instructions.
Enzyme linked immunosorbent assay (ELISA). This was carried out as described
previously with unpermeabilised cells to quantify cell surface expression32. Briefly,
HEK293 cells expressing the hGLP-1R were serum starved for 1 h and then
stimulated without or with agonist at 37uC/5% CO2. Where indicated, cells were
incubated without or with inhibitors for 30 min prior to stimulation with agonist at
37uC/5%CO2. Cells were then fixed with 4% paraformaldehyde (PFA) for 5 min and
non-specific binding sites blocked with 1% bovine serum albumin (BSA)made in Tris
buffered saline (TBS) (1% BSA/TBS) for 45 min. Cells were incubated with either the
anti-hGLP-1R or anti-VSVG mouse antibody (diluted 1515000) in 1% BSA/TBS for
1 h, washed with TBS and then incubated with the HRP-conjugated anti-mouse IgG
(diluted 155000) in 1% BSA/TBS for 1 h. Cells were washed and developed using 1-
step Ultra TMB-ELISA substrate (Bio-Rad) for 15 min and the reaction stopped by
adding an equal volume of 2 M sulphuric acid. The optical density was read at
450 nm using a plate reader.
Immunofluorescence. Intracellular localisation of hGLP-1R expression was assessed
by immunofluorescence as described previously32. Briefly, cells were serum starved
for 1 h and where indicated cells were pre incubated without or with inhibitors at the
indicated concentration for 30 min. Cells were then incubated with either the anti-
hGLP-1R or anti-VSVGmouse antibody (diluted 155000) in 1% BSA/DMEM for 1 h
at 4uC and then stimulated without or with agonist in the presence of inhibitor at
37uC/5% CO2. Cells were then fixed with 4% PFA for 30 min. Cells were
permeabilised with 0.2% Triton X-100 made in phosphate buffered saline (PBS) for
10 min, blocked in blocking buffer (1% BSAmade in wash buffer [0.1% Triton X-100
in PBS]) for 30 min and then incubated with the Cy3-conjugated anti-mouse
antibody (diluted 15200 in blocking buffer) for 1 h. Cells were then washed 3 times
with wash buffer and incubated with DAPI (49,6-diamidino-2-phenylindole
dihydrochloride, 1 mg/ml) diluted 152000 in PBS to stain nucleus. Coverslips were
mounted on glass microscopic slides using mounting solution (0.1 M Tris-
hydrochloric acid [HCl], pH 8.5, 10% Mowiol 50% glycerol) containing 2.5%
DABCO (1,4 diazabicyclo (2.2.2) octane). Immunofluorescence staining was
Figure 8 | Proposed schematicmodel of hGLP-1R cell surface expression as deduced from the present study.Within the ER the SP is cleaved to revealN-
linked glycosylation sites. The receptor is then glycosylated within the ER and Golgi prior to trafficking to the plasma membrane.
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visualised using a Zeiss LSM710 confocal microscope fitted with a 633 oil immersion
lens.
cAMP assay. Cells were serum starved for 1 h and then stimulated without or with
100 nM GLP-1 for 1 h at 37uC/5% CO2 in the presence of 0.25 mM
phosphodiesterase inhibitor Ro201724. Cells were lysed and cAMP levels in the cell
lysates were estimated using the cAMP direct immunoassay kit (Abcam).
Flow cytometry. Cells in suspension were incubated in blocking buffer (0.2% BSA/
PBS) for 1 h at 4uC and then with either the anti-hGLP-1R or anti-VSVG mouse
antibodies (diluted 15100 in blocking buffer) for 1 h at 4uC. Cells were washed 3 times
with PBS and incubatedwith theCy3-conjugated anti-mouse antibody, diluted 15100
in blocking buffer for 1 h at 4uC in the dark. Cells were washed 3 times and incubated
with 7-aminoactinomycin D (7-AAD) diluted 15100 in blocking buffer for 5 min at
4uC in the dark. Cells were resuspended in 1 ml fluorescence-activated cell sorting
(FACS) buffer (0.2% BSA, 0.05% sodium azide in PBS) and analysed using BD FACs
Aria flow cytometer (BD Bioscience) and BD FACS DIVA software.
Cell lysates.Tomake cell lysates, HEK293 cells expressing the hGLP-1R were washed
3 times with ice cold PBS and lysed in ice cold modified RIPA lysis buffer (10 mM
Tris-HCl, pH 7.5, containing 10 mM ethylenediaminetetraacetic acid [EDTA], 1%
nonyl phenoxypolyethoxylethanol [NP40], 0.1% sodium dodecyl sulphate [SDS],
0.5% sodium deoxycholate and 150 mM Sodium Chloride [NaCl]) with 1%
mammalian protease inhibitors. Cell lysates were incubated at 4uC for 15 min and
then centrifuged at 22000 3 g for 10 min at 4uC. The supernatant was collected and
K volume of 33 SDS-polyacrylamide gel electrophoresis (PAGE) sample loading
buffer (75 mM Tris HCl, pH 6.8 containing 3% SDS, 30% glycerol, 0.003%
bromophenol blue and 0.3 M dithiothreitol [DTT]) was added and left at room
temperature for 1 h. These cell lysates were used to hGLP-1R expression by
immunoblotting using the anti-GFP and anti-VSVG antibodies.
Surface biotinylation. This was performed as described previously13. Cells were
washed with ice cold PBS containing 1 mM calcium chloride (CaCl2) and 1 mM
magnesium chloride (MgCl2) and incubated at 4uC for 1 h with 0.5 mg/ml Sulpho-
NHS-LC-Biotin (Thermo Scientific). Cells were then incubated for 10 min at 4uC
with 100 mMglycine in TBS to quench any remaining reactive biotin cross linker and
lysed in ice cold modified RIPA lysis buffer with 1% mammalian protease inhibitors.
Cell lysates were incubated with Streptavidin Magnetic Beads (Invitrogen) at 4uC for
2 h. Beads were washed 3 times with lysis buffer and the bound protein eluted in 13
SDS-PAGE sample loading buffer (25 mM Tris HCl, pH 6.8, containing 1% SDS,
10% glycerol, 0.001% bromophenol blue and 0.1 M dithiothreitol [DTT]). The lysate
not incubatedwith beads wasmixedwithK volume of 33 SDSPAGE sample loading
buffer and used to assess total hGLP-1R. Total and biotinylated cell surface receptors
were detected by immunoblotting.
Immunoblotting. Proteins were separated in a SDS-PAGE gel by electrophoresis and
transferred onto polyvinylidene fluoride (PDVF) membrane33. Membranes were
blocked with TBST (TBS with 0.1% tween 20) containing 5% milk powder (blocking
buffer) for 1 h at room temperature or overnight at 4uC. Membranes were
immunoblotted with the anti-GFPmouse antibody (diluted 15500 in blocking buffer)
for 1 h at room temperature or overnight at 4uC. Membranes were washed and then
incubated with the HRP-conjugated anti-mouse secondary antibody (diluted 152500
in blocking buffer) for 1 h at room temperature. Membranes were then incubated in
ECL select substrate and bands visualised using the ChemiDocTM XRS system (Bio-
Rad)34,35. Blots probed with the anti-GFPmouse antibody were stripped with western
blot stripping buffer (Thermo Scientific) and reprobed with the anti-VSVG rabbit
antibody (diluted 151000) in blocking buffer) and the HRP-conjugated anti-rabbit
secondary antibody (diluted 152500 in blocking buffer) as described above.
Tunicamycin treatment. This was carried out as described previously20. Briefly, cells
were treated with 5 mg/ml tunicamycin at the time of transfection. After 48 h of
transfection, cells were lysed and subjected to immunoblotting.
Glycosidase treatment. This assay was carried out as described previously14. Cells
harvested from a 10 cm plate by trypsinisation were resuspended in 1 ml
homogenisation buffer (10 mM Tris HCl, pH 7.5, 1 mM EDTA, 1 mM
phenylmethanesulfonylfluoride [PMSF]) containing 1% mammalian protease
inhibitors and incubated on ice for 15 min. Cells were then sonicated at 80%
amplitude for 3 3 10 sec with 1 min intervals. The lysate was centrifuged at 300 3 g
for 10 min at 4uC to pellet nuclei and unbroken cells. An aliquot of post-nuclear
supernatant fraction (50 mg of protein) was incubated with glycoprotein denaturing
buffer at room temperature for 1 h and then treated without or with 500 units of
either PNGase F or Endo H for 1 h at 37uC. Reactions were stopped with the addition
ofK volume of 33 SDS-PAGE sample loading buffer and subjected to
immunoblotting.
Data analysis. Data were analysed using the GraphPad Prism program. All data are
presented as means 6 standard error of the mean (SEM) of three independent
experiments. Statistical comparisons between a control and test value was made by a
two-tailed unpaired student t-test. Statistical analysis between multiple groups were
determined by the Bonferroni’s post test after one-way or two-way analysis of
variance (ANOVA), where p . 0.05 was considered as statistically not significant
(n.s.), and p, 0.05, p, 0.01 and p, 0.001 shown as *, ** and *** respectively, was
considered statistically significant. Concentration response curves were also fitted
using Prism, according to a standard logistic equation. Confocal images shown in the
figures are representative of 190–200 transfected cells from three different
experiments. Similarly, immunoblotting data shown in the figures are representative
of three independent experiments.
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